Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10700763 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL11765786 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL29376049 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL14959945 | 1.00 | FOLH1 (0.53) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL29663724 | 0.97 | FOLH1 (0.50) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL30731558 | 0.97 | FOLH1 (0.50) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL30714839 | 0.96 | FOLH1 (0.52) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL30731559 | 0.94 | FOLH1 (0.51) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL29960118 | 0.92 | FOLH1 (0.46) | FOLH1GSRCPB2ERAP2ERAP1 | |
| SCHEMBL30223699 | 0.91 | FOLH1 (0.62) | FOLH1GSRCPB2SLC6A5NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117838878-A | Antibody-STING agonist conjugates and their use in immunotherapy | 免疫传感器治疗股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-112794881-B | Anti-liver cancer tridecapeptide NKSGTYSNDDLSH and preparation method thereof | 黑龙江省科学院大庆分院 | 2023-10-31 | — | — | CN | claimed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | claimed |
| CN-115427051-A | Therapeutic agents and conjugates thereof | 北京轩义医药科技有限公司 | 2022-12-02 | — | — | CN | claimed |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | EXELIXIS, INC. | 2022-08-18 | — | — | US | claimed |
| EP-3999118-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | Immunesensor Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3994150-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Iconic Therapeutics, Inc. (US) | 2022-05-11 | — | — | EP | claimed |
| EP-3320923-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260042847-A1 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | ZYMEWORKS INC (CA) | 2026-02-12 | — | — | US | disclosed |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ASTRAZENECA AB (SE) | 2026-02-05 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | IMMUNOME INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-114222752-A | Anti-tissue factor antibody-drug conjugates and related methods | 伊科尼克治疗公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114025795-A | Methods of treating biliary tract cancer using bispecific antigen-binding constructs targeting HER2 | 酵活有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-7148203-B2 | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-12-12 | — | — | US | disclosed |
| EP-0267629-A2 | Polypeptides having interleukin-1 activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042847-A1 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | BCR, CLTC, CARS1 | FOLH1 490/4885GSR 1406/4885CPB2 2162/4885 |
| US-20220257789-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | F3, F13B, TFPI | FOLH1 171/4885GSR 4776/4885CPB2 331/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | FOLH1 438/4885GSR 4473/4885CPB2 375/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | FOLH1 2112/4885GSR 4343/4885CPB2 2435/4885 |
| US-20260028420-A1 | ANTI-TUMOR ANTIBODIES | B4GALT1, ST6GAL1, GALNT3 | FOLH1 339/4885GSR 4632/4885CPB2 467/4885 |
| US-20260036547-A1 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | ATP5ME, ATP5MF, ATP5MK | FOLH1 1926/4885GSR 986/4885CPB2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.